A citation-based method for searching scientific literature

Barbara M Norquist, Maria I Harrell, Mark F Brady, Tom Walsh, Ming K Lee, Suleyman Gulsuner, Sarah S Bernards, Silvia Casadei, Qian Yi, Robert A Burger, John K Chan, Susan A Davidson, Robert S Mannel, Paul A DiSilvestro, Heather A Lankes, Nilsa C Ramirez, Mary Claire King, Elizabeth M Swisher, Michael J Birrer. JAMA Oncol 2016
Times Cited: 331



Bella Kaufman, Ronnie Shapira-Frommer, Rita K Schmutzler, M William Audeh, Michael Friedlander, Judith BalmaƱa, Gillian Mitchell, Georgeta Fried, Salomon M Stemmer, Ayala Hubert, Ora Rosengarten, Mariana Steiner, Niklas Loman, Karin Bowen, Anitra Fielding, Susan M Domchek. J Clin Oncol 2015
Times Cited: 962




List of shared articles



Times cited

The RAD51D c.82G>A (p.Val28Met) variant disrupts normal splicing and is associated with hereditary ovarian cancer.
Ciyu Yang, Angela G Arnold, Amanda Catchings, Vikas Rai, Zsofia K Stadler, Liying Zhang. Breast Cancer Res Treat 2021
0


Plasma Protein Biomarkers Associated with Higher Ovarian Cancer Risk in BRCA1/2 Carriers.
Hee-Sung Ahn, Jung Yoon Ho, Jiyoung Yu, Jeonghun Yeom, Sanha Lee, Soo Young Hur, Yuyeon Jung, Kyunggon Kim, Youn Jin Choi. Cancers (Basel) 2021
0

Epithelial ovarian cancer risk: A review of the current genetic landscape.
Nicola Flaum, Emma J Crosbie, Richard J Edmondson, Miriam J Smith, Dafydd G Evans. Clin Genet 2020
7

Prevalence of hereditary breast and ovarian cancer (HBOC) predisposition gene mutations among 882 HBOC high-risk Chinese individuals.
Di Shao, Shaomin Cheng, Fengming Guo, Changbin Zhu, Yuying Yuan, Kunling Hu, Zhe Wang, Xuan Meng, Xin Jin, Yun Xiong,[...]. Cancer Sci 2020
6

A phase 1 dose-escalation study of intraperitoneal cisplatin, intravenous/intraperitoneal paclitaxel, bevacizumab, and olaparib for newly diagnosed ovarian cancer.
Karen A Cadoo, Rachel N Grisham, Roisin E O'Cearbhaill, Nicole N Boucicaut, Melissa Henson, Alexia Iasonos, Qin Zhou, Debra M Sarasohn, Jacqueline Gallagher, Sara Kravetz,[...]. Gynecol Oncol 2020
1

Emerging drugs for the treatment of ovarian cancer: a focused review of PARP inhibitors.
Elizabeth K Lee, Ursula A Matulonis. Expert Opin Emerg Drugs 2020
1